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Abstract 
The human complement factor B is a centrally important component of the alternative 
pathway activation of the complement system. Here we report the isolation, characterization 
and eukaryotic expression of the first full length cDNA transcript for human factor B. In a 
factor B dependent haemolysis assay, the recombinant human factor B generated by transient 
COS cell transfection was shown to reconstitute haemolytic activity of factor B depleted 
human serum. To study the biological activities assigned to factor B, the availability of 
recombinant polypeptides representing definite portions of the human factor B molecule is 
desirable. 
Introduction 
The human complement factor B is one of the six components that 
constitute the alternative pathway activation of the complement system 
which provides an antibody independent route for the destruction of 
bacteria, neutralization of viruses and lysis of certain mammalian cells (1,2). 
Factor B is a heat-labile, single-chain glycoprotein of 93 kDa which is 
contained in human plasma in its zymogen form at a concentration of 
100-400 mg/1. In the presence of magnesium ions, factor B binds to fluid 
phase or surface bound C3b or hydrolysed C3 (C3H 20) forming a C3bB 
proenzyme complex. This complex is the substrate for the cleavage of factor 
B by a serum protease, factor D. Immediately upon removal of a 30 kDa 
: :' This study was supported by Deutsche Forschungsgemeinschaft (DFG, grant Di 245/4-1). 
+ This work is in partial fulfillment of T. Sokolowski's MD thesis. 
0 Recipient of a professorship of the Stifterverband für die Deutsche Wissenschaft. 
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aminoterminal fragment (Ba) of factor B, the remaining C3bBb complex 
expresses C3 convertase activity. The conversion of C3 to C3a and C3b 
again forms an important amplification loop as nascent C3b may initiate the 
generation of other C3bBb complexes. Activation of the alternative path-
way ends in the assembly of the C5 convertase which is created by binding 
of an additional C3b molecule in close proximity to the C3bBb complex. 
These complexes, C3bBb and C3b2Bb, have a short half-life in solution 
since they are subject to spontaneous as well as factor-H-mediated decay 
dissociation (3, 4). Therefore, the activation of the alternative pathway is 
centrally regulated by properdin, a serum component that stabilizes these 
enzymes (5, 6). Besides the zymogen function, additional biological 
activities have been observed for both the Ba and the Bb fragments of factor 
B. Purified human Ba was shown to inhibit proliferation of preactivated 
human B lymphocytes by binding to a distinct cell surface receptor (7), 
whereas purified Bb was shown to enhance proliferation of preactivated 
human B lymphocytes and to act synergistically with IL-2 and B cell 
growth factor by binding to the high molecular weight B cell growth factor 
receptor which induces B lymphocyte differentiation into antibody-secret-
ing cells (8). Furthermore, purified Bb was shown to induce the rapid 
spreading of human peripheral blood monocytes (9), to stimulate lympho-
cyte blastogenesis (10), to promote the intracellular killing of Staphylococ-
cus aureus by human peripheral blood monocytes (11), and to enhance the 
cell mediated lysis of xenogenic erythrocytes by human peripheral blood 
monocytes (12). 
The structure and organization of the human factor B gene within the 
class I I I region of the major histocompatibility complex (MHC) on the 
short arm of chromosome 6 (13) has been determined by gene cloning (14, 
15). The entire amino acid sequence of human factor B has been established 
combining both peptide sequencing and translation of the partial nucleotide 
sequences of cDNA and cosmid clones (14-19). In this contribution, we 
present the first full-length cDNA transcript for human factor B and the 
functional analysis of the recombinant zymogen obtained by expressing this 
cDNA in COS cells. 
Materials and Methods 
Construction and screening of a human cDNA library in the eukaryotic expression vector 
CDM8 
RNA was prepared from human liver tissue by extraction with guanidinium thiocyanate and 
centrifugation through a cesium chloride gradient (20). Poly(A)+ RNA was purified by 
oligo(dT) cellulose chromatography. Approximately 15 u.g (poly(A)+ RNA was employed for 
cDNA synthesis using a kit supplied by BRL, Karlsruhe, Germany. Size-selected cDNA 
fragments (> 1 kb) were ligated with Bst X I linker and cloned into purified Bst Xl-linearized 
vector C D M 8 , following exactly the protocol provided by Dr. B. SLLD, Boston, MA, USA (21 , 
22). About 300,000 colonies were screened with cDNA probe FBI (kindly provided by Dr. R. 
D. CAMPBELL, Oxford, UK) representing ca. 500 bp of the human factor B mRNA (14). 
Positive colonies were subjected to a rescreening procedure which yielded five different cDNA 
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clones for human factor B, termed pFBl-5. These clones were further charcterized by 
restriction enzyme analysis and cDNA sequencing. 
DNA sequence analysis 
To determine whether one or more of the potential factor B clones contained the complete 
coding sequence of the factor B mRNA, the cDNA insertions from each of the five clones 
were partially sequenced from both ends, using oligonucleotides, ocdm8-l (CTGGCTAAC-
TAGAGAAC) located 5' and ocdm8-2 (GATCCTCTAGAGTCGC) located 3' of the Bst X I 
cloning site. DNA sequence analysis was performed with T7 polymerase and the reagent kit 
supplied by Pharmacia, Freiburg, Germany. 
Northern blot analysis 
Total RNA was prepared by the method of CHIRGWIN et al. (20), quantified by measuring 
the absorbance at 260 nm. 10 ug were separated on a formaldehyde-containing 1.2% agarose 
gel and blotted to Hybond N filters. Agarose gel electrophoresis, RNA transfer and hybridiza-
tion of blots were performed by standard techniques (23). Poly (A+) RNA was selected from 
total RNA preparations using the «mRNA Purification Kit» (Pharmacia). Factor B cDNA was 
labeled with 3 2P-dATP using the random priming method (24). The probe was used at a 
concentration of 5 x 106 cpm of labelled cDNA/ml hybridization solution. Hybridization and 
washing of the Northern blots was carried out according to the method described by CHURCH 
and Gii.BF.RT (25). The last washing step was performed in 0.3xSSC/0.1 % SDS for l h at 
65 °C. 
COS cell transiection 
The factor B cDNA in the vector CDM8 was transfected into COS-7 cells via electropora-
tion using a Gene Pulser apparatus (BioRad, Munich, Germany). Prior to transfection, 1 x 107 
COS cells in suspension were washed in sucrose buffer (272 inM sucrose, 7 mM Na 2 HP0 4 pH 
7.4, 1 mM MgCL) and resuspended in 0.8 ml sucrose buffer. The suspension was transferred to 
a 0.4 cm electroporation kuvette (BioRad) and 30 u.g DNA were added. The sample was 
incubated on ice for 10 min and then electroporated at 25 up and 400 V. Then the cells were 
incubated for an additional 10 min on ice and transferred to a cell culture bottle containing 15 
ml DM EM and 10% FCS. After overnight incubation at 37 °C the culture supernatant was 
collected and centrifuged. The cells were resuspended in 30 ml CG-medium and added to the 
remaining adherent COS cells. 84 h post transfection, the supernatant was collected and 
subjected to a Western blot analysis. As a control, supernatant from nontransfected COS cells 
was loaded on the same gel. 
Western blot analysis 
Supernatant of COS cell transfectants (5 ul) were analyzed by SDS-PAGE on a 9-15% 
gradient gel under nonreducing conditions (26) and blotted to nitrocellulose according to the 
method of TOWBIN et al. (27). Blots were stained with a polyclonal goat anti-human factor B 
antibody (purchased by Quidel, San Diego, CA, USA) and peroxidase-conjugated anti-goat 
IgG (purchased by Dakopatts, Hamburg, Germany) using standard protocols. 
Factor B ELISA 
An enzyme-linked immunosorbent assay (ELISA) was carried out for factor B on microtiter 
plates (78-381-04, Flow Laboratories, UK). The wells were coated overnight at 4°C with 5 ug/ 
ml of rabbit anti-human factor B IgG (Quidel). The plates were washed five times in PBS/ 
tween-buffer and blocked with PBS/tween-buffer containing BS A (10 mg/ml) for 1 h at room 
temperature. After washing 5x with PBS/tween-buffer, the samples (100 ul) containing factor 
B were applied in PBS/tween-buffer containing BSA (0.5 mg/ml) and dilutions made in the 
same buffer. To quantify the relative amount of factor B contained in supernatant of the COS 
cells transfected with cDNA clone pFB2, a standard curve was drawn with dilutions of normal 
human serum at 1:2000, 1:4000, 1:8000, 1:16,000, 1:32,000, 1:64,000, 1:128,000, and 1:256,000 
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which correspond to 100, 50, 25, 12.5, 6.25, 3.12, 1.56, and 0.78 ng of serum factor B per ml. 
The samples were incubated at 4°C in a moist box overnight. After washing 5x in PBS/tween-
buffer, the bound factor B was detected by the addition of biotinylated rabbit anti-human 
factor B IgG (150 ul of 1:2000 dilution of 10 mg/ml biotinylated antibody IgG fraction) 
followed by streptavidin-alkaline phosphatase (150 ul of 1:10,000 dilution of 1 mg/ml 
solution). Finally phosphatase substrate (Sigma 104; 50 ul of 1 mg/ml in pH 9.5 development 
buffer) was added and the absorbancy was measured at 405 nm. The assay was sensitive to a 
level of 0.1 ng/100 ul of sample. 
Haemolytic assay 
Factor B activity was determined in a haemolysis assay measuring the formation of C3bBbP 
on EAC43b cells (28) by the ability of culture supernatant to restore lysis of rabbit 
erythrocytes by factor B depleted serum. Fifty microliters of supernatant of pFB2 transfected 
COS cells were mixed with 50 \i\ of factor B-depleted human serum (purchased from Quidel) 
and rabbit red blood cells (2 x 108 in 25 ul of PBS-Mg++-EGTA), and incubated at 37 °C for 15 
min. After addition of ice-cold PBS-Mg++-EGTA (1.0 ml), the samples were spun (10 min at 
1500 rpm) and the degree of lysis estimated from the E 1 cm/412 nm of the supernatants. 
Results 
Isolation and sequence analysis of the full-length cDNA clone pFB2 
Five potential factor B cDNA clones obtained the human liver cDNA 
library were subjected to a Northern blot analysis. All of them strongly 
hybridized to a mRNA species of ca. 2.6 kb in human liver RNA (not 
shown). The orientation of the cDNA clones was determined by digestion 
with Hindl l l which cuts in the 5' region of the human factor B cDNA and 
in the 5' linker sequence of the vector CDM8 (see Fig. 1). Three of the five 
potential factor B clones were found to contain a cDNA insert in the 
correct 5' to 3' orientation. Sequencing of the 5' and 3' ends of the inserts 
confirmed the orientation and revealed that one of these clones, pFB2 
potentially comprises the entire coding sequence of the factor B mRNA. 
Therefore, the complete cDNA sequence of 2447 bp contained in pFB2 was 
determined. As shown in Figure 2 pFB2 comprises 111 nucleotides of a 5' 
untranslated region, followed by an open reading frame of 2292 bp, 
200bp 
Figure 1. Full-length factor B cDNA pFB2 in the vector CDM8. The restriction map of pFB2 
is shown for the following restriction enzymes: E, Eco RI; H , Hind I I I ; P, Pst 1. Short 
horizontal arrows show the direction of DNA sequence determination with oligonucleotides 
localized in the CDM8 linker region or the internal cDNA sequence. Sites marked with an 
asterisk are located in the CDM8 polylinker sequence. 
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encoding a typical leader peptide of 25 amino acids and the entire 739 amino 
acids of mature factor B. The coding sequence is followed by a stop codon 
(position 2404) and a 3'untranslated region of 41 bp containing a poly-
adenylation signal (ATTAAA) 33 bp downstream of the stop codon. A 
comparison between the nucleotide sequence of pFB2 and previously 
published partial cDNA and genomic sequences is given in Figure 1. 
Partial exon sequencing data which have been determined from the factor 
B specific cosmid Cos 10 (15) were aligned over a stretch of 408 bp to the 
corresponding sequence at the 5' end of pFB2. The comparison revealed 
that the 5' untranslated region of pFB2 starts 18 bp downstream from the 
mRNA start site contained in Cos 10. The 5' sequence of pFB2 is in total 
agreement with the sequence of the two exons analyzed in Cos 10. The 
pFB2 sequence confirms that no intron interrupts the 5' untranslated and 
the coding sequence for the signal peptide as previously determined by a Si 
nuclease mapping analysis of Cos 10. 
Moreover, the 3' portion of pFB2 was colinear with the sequence of 
eleven exons analyzed in another factor B cosmid, termed Cosl (14). 
Within this 1299 bp stretch, one transition (a «G» in Cosl instead of an «A» 
in position 1966 of the pFB2 sequence) was observed which results in an 
amino acid exchange in the derived factor B peptide sequence («GAG» 
codes for glutamic acid in the Cosl sequence instead of «AAG coding for 
lysine in pBF2). Furthermore, the pFB2 sequence was aligned to three other 
previously published partial cDNA sequences for human factor B, the 
cDNA FBI (14) that was used to isolate pFB2, the cDNA pFB3a (15) 
containing the coding sequence for the Ba fragment of factor B in a reversed 
orientation, and the cDNA pBfA28 (18) that comprises the coding region 
for the entire Bb fragment. The alignment of the 515 bp long FBI sequence 
shows silent exchanges in two nucleotide positions, one transition at 1326 
(«T» in the FBI sequence instead of a «C» in the pFB2 sequence) and a 
transversion in position 1422 («C» in the FBI sequence instead of a «G» in 
pFB2). A comparison of the pFB2 sequence with the 710 bp long coding 
sequence for the Ba fragment contained in pFB3a revealed total identity. 
The alignment of the pFB2 sequence with pBfA28 includes a stretch of 2075 
bp. Within this length, pBFA28 differs from the pFB2 sequence in sixteen 
nucleotide positions. The substitutions in the positions 552, 561, 663, 1194, 
1401, 1632, 1755, 1770, 1821, and 2316 do not alter the derived amino acid 
sequence whereas the transversions in the positions 1009 («CTG» coding 
for leucine in pBfA28 instead of «GTC» coding for valine in pFB2) and 
Figure 2 (see next pages). Nucleotide sequence of the full length cDNA clone pFB2 in • 
comparison with all other as yet published cDNA and exon sequence data for human factor B. 
The protein coding region is shown in capital letters. Identity between pFB2 and the compared 
sequence is indicated by dots. Wherever an aligned sequence differs from the sequence of 
pFB2, the divergent base is given below. The polyadenylation signal, ATTAAA, in the 
3'untranslated region is shown in bold type underlined. 
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10 20 30 40 
caggtctaggt ctggagt t tcagct tggacactgagccaagcagac 
60 70 80 90 
rccaggacacaccatcctgccocaggoccagct pFB2 
, CoslO 
100 110 120 130 140 150 160 170 180 
tctctoctgccttocaacgacATCm^^ pFB2 
CoslO 
pFB3a 
190 200 210 220 230 240 250 260 270 
AXACCACTOATOSICITro pFB2 
CoslO 
pFB3a 
280 290 300 310 320 330 340 350 360 
(^<3J0CCA(XX3HJK^K^ pFB2 
CoslO 
pFB3a 
370 380 390 400 410 420 430 440 450 
pcceTGW&crcmzcc^^ PFB2 
CoslO 
pFB3a 
pBfA28 
460 470 480 490 500 510 520 530 540 
TACTOQOCmSSICI^^ pFB2 
pFB3a 
pB£A28 
550 560 570 580 590 600 610 620 630 
?C?lXXX2&GTGmFX£^ pFB2 
pFB3a 
C A pBfA28 
640 650 660 670 680 690 700 710 720 
PCKKZMOJKXXm^ pFB2 
pFB3a 
G pBfA28 
730 740 750 760 770 780 790 800 810 
ACGTCICAGGA03GTOC£^^ pFB2 
pFB3a 
820 830 840 850 860 870 880 890 900 
TirjcrcirjTirariG^^ PFB2 
pFB3a 
pBfA28 
910 920 930 940 950 960 970 980 990 
GAOCCITCÄGQCK^ pFB2 
pBfA28 
1000 1010 1020 1030 1040 1050 1060 1070 1080 
G i r ^ C H M T I G S G A ^ ^ pFB2 
C pBfA28 
1090 11O0 1110 1120 1130 1140 1150 1160 1170 
GTGICTCAAQCÄ^^ pFB2 
FBI 
Cosl 
T pB£A28 
1180 1190 1200 1210 1220 1230 1240 1250 1260 
MO^CCMGMOXCCTC^ pFB2 
FBI 
Cosl 
G.AG.A A pBfA28 
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1270 1280 1290 1300 1310 1320 1330 1340 1350 
ATCATOTTCAflXACT^ pFB2 
T FBI 
Cosl 
pBfA28 
1360 1370 1380 1390 1400 1410 1420 1430 1440 
GATCQCAAAAACD^ AAC<X]WX^  pFB2 
C FBI 
Cosl 
G pBfA28 
1450 1460 1470 1480 1490 1500 1510 1520 1530 
TOCÄAGÄABSÄC^^ pFB2 
FBI 
Cosl 
pBfA28 
1540 1550 1560 1 570 1580 1590 1600 1610 1620 
TUIXITXAGICTCTC pFB2 
FBI 
Cosl 
pBfA28 
1630 1640 1650 1660 1670 1680 1690 1700 1710 
CCTIÜVAG3GAC/03?^ pFB2 
FBI 
Cosl 
C pBfA28 
1720 1730 1740 1750 1760 1770 1780 1790 1800 
GMCACnCAATCA^OJICACCJr^ pFB2 
Cosl 
C A pBfA28 
1810 1820 1830 1840 1850 1860 1870 1880 1890 
AAAAAAGAAGCAGGAATIOC^ ^ pFB2 
Cosl 
C pBfA28 
1900 1910 1920 1930 1940 1950 1960 1970 1980 
axÄTnrncTOocro^ pFB2 
G Cosl 
pBfA28 
1990 2000 2010 2020 2030 2040 2050 2060 2070 
(XTQCACAGGMATCAMGCT^^ pFB2 
Cosl 
pBfA28 
2080 2090 2100 2110 2120 2130 2140 2150 2160 
(TXIAQCTCTIGACACAGATTX^  pFB2 
\ . Cosl 
pB£A28 
2170 2180 2190 2200 2210 2220 2230 2240 2250 
C<ÄCÖ£rPGAGT^ pFB2 
Cosl 
pBfA28 
2260 2270 2280 2290 2300 2310 2320 2330 2340 
CTTCXnrjITWiraGeramO^ pFB2 
Cosl 
C pBß£8 
2350 2360 2370 2380 2390 2400 2410 2420 2430 
MOTIUITICAAGIGTia^ pFB2 
Cosl 
pB£A28 
2440 2450 
tgggattg^attaaaac pFB2 
Cosl 
pBfA28 
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1094 («GTC» coding for valine in pBfA28 instead of «GAC» coding for 
aspartic acid in pFB2) lead to changes in the derived amino acid sequence. 
In addition, two inversions also lead to changes in the derived amino acid 
sequence, one in position 1177-1179 («AAG» coding for lysine in pFB2 
instead of «GAA» coding for glutamic acid in pBfA28) and another in 
position 1180-1183 («GAA» coding for glutamic acid in pBfA28 instead of 
«AAG» coding for lysine in pFB2). The cDNA sequence of pFB2 com-
pletes the pBfA28 sequence in sections where the nucleotide sequence was 
not determined or ambiguity was observed between the cDNA sequence 
data and the determined protein sequence (see gaps indicated by the 
omission of dots). Two of these gaps in the pBfA28 sequence were also not 
filled by any of the other as yet published cDNA or exon sequence data. 
For these sections, the pFB2 cDNA adds a novel coding sequence which 
taken together comprises 16 nucleotide residues. The peptides encoded by 
this added sequence are consistent with the protein sequencing data (15-18). 
Eukaryotic expression of a recombinant zymogen for human factor B 
As the liver cDNA library was constructed in the eukaryotic expression 
vector CDM8, the cDNA was tested directly for the encoded protein by 
transient expression in COS cells (21, 22). Three days after transfection, the 
1 2 3 4 
Figure 3. Western blot analysis for factor B expression in Cos cell transfectants. 50 ul of 
supernatant from different transfection assays were subjected to SDS-PAGE under nonreduc-
ing conditions and then analyzed by Western blotting with a polyclonal goat anti-human 
factor B antiserum. Lane 1: 5 ul supernatant from 15 x 10f> COS cells transfected with pFB2, 
lane 2: 5 ul supernatant from 5 x 106 COS cells transfected with pFB2, lane 3: 5 ul supernatant 
from 9 x l 0 6 COS cells transfected with pFB2, lane 4: 5 ul supernatant from 15x106 
nontransfected COS cells. On the right, the position of the sizemarkers is indicated in kDa. 
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Table 1. Haemolytic activity of serum factor B and the recombinant factor B secreted by pFB2 
transfected COS cells 
Factor B (Hg/ml)a (em/ml)b (em/jig) 
Control0 0 0 0 
Prep 1 7.4 86.3 x 107 11.7 x 107 
Prep 2 1.0 26.0 x 107 26.0 x 107 
Prep 3 2.0 36.4 x 107 18.2 x 107 
Serum 151.0 5.6 x 1010 37.1 x 107 
,x Factor B protein concentration (ug/ml) measured by ELISA. 
h Factor B functional activity (expressed as effective molecules/ml) measured by haemolytic 
assay. 
c Supernatant from COS cells transfected with the expression vector CDM8 without a cDNA 
insertion was assayed as a negative control. 
supernatants were assayed in duplicate in a factor B ELISA. The relative 
amount of recombinant factor B secreted by the COS cells was determined 
in reference to the factor B concentration in a standard dilution of human 
serum. Supernatants from three pFB2 transfections, done with different 
numbers of COS cells, were analyzed. In a transfection of 15xi0 6 COS 
cells (Prep 1), the relative amount of recombinant factor B was determined 
to be ca. 7.4 [Ag/ml. The supernatant from two other transfection assays of 
5 x 106 and 9x 106 COS cells (Prep 2 and Prep 3) were found to contain a 
relative amount of 1.0 fxg/ml and 2.0 u,g/ml factor B respectively. These 
results correspond to a relative amount of 3-8 j ig of recombinant factor B 
secreted by 106 COS cells. To confirm the ELISA results, the supernatants 
were subjected to a Western blot analysis. As shown in Figure 3, in all 
supernatants from pFB2 transfections, a single band of the expected size of 
ca. 93 kDa was stained with a polyclonal factor B antiserum (see lanes 1-3). 
The intensity of staining corresponds to the relative abundance of recom-
binant factor B measured in the ELISA. As a negative control, supernatant 
from nontransfected COS cells was loaded in lane 4. 
Haemolytic assay tor functional activity of recombinant factor B 
Recombinant factor B was functionally active as ascertained by haemoly-
tic assay. The haemolytic activity of serum factor B and the culture 
supernatants from the three different COS cell transfections was assayed in 
triplicate. The mean values of the assays are shown in Table 1. 
When calculating the number of effective molecules per microgramm of 
factor B, the recombinant human factor B expressed nearly the same 
functional activity as factor B in normal human serum. 
Discussion 
The availability of the first correct full-length cDNA transcript of human 
factor B mRNA made it possible to generate a recombinant zymogen for 
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the activation of the alternative pathway of the complement system. The 
nucleotide sequence of the cDNA contained in clone pFB2 completes the 
fragmentary cDNA sequence data determined from previously published 
partial cDNA clones for human factor B. At the 5' end, the pFB2 sequence 
adds 156 residues to the known cDNA sequence for factor B and confirms 
the corresponding genomic sequence data obtained from a factor B cosmid. 
Moreover, the cDNA sequence of pFB2 adds 16 residues of the nucleotide 
sequence in the coding region of the factor B mRNA which were neither 
contained in the previous cDNA nor in the genomic sequence data deter-
mined for the factor B gene. An alignment between the pFB2 sequence to all 
the as yet known nucleotide sequence data for factor B revealed a polymor-
phic structure for factor B mRNA. The pFB2 sequence can be related to the 
S allele of the factor B gene as in amino acid position seven of the mature 
protein. pFB2 codes for an arginine, which is specific for the BF S type, 
instead of a glutamine in the BF F allotype (29, 30). Of the observed 
nucleotide substitutions, one seen in comparison with the Cosl sequence 
and three seen in comparison with the pBfA28 cDNA resulted in changes in 
the encoded peptide sequence. The transfection assays with pFB2 have 
shown, that a reasonable amount of recombinant human factor B can be 
expressed in COS cells. In a factor B-dependent haemolysis assay, the 
translational product of pFB2 was shown to express functional activity. The 
number of effective molecules per microgramm of recombinant factor B 
varied between the different transfection assays, but was nearly the same as 
that of its natural serum counterpart. A reconstitution of the alternative 
pathway activation by the recombinantly expressed zymogen requires that 
the generated peptide can efficiently bind to C3b or C3(H 20), that the 
peptide can be converted subsequently to Bb in a factor D mediated 
cleavage, and that the Bb portion of this recombinant factor B exhibits 
serine esterase activity for the conversion of C3 to C3b. As most of the 
functional sites of factor B have recently been mapped on proteolytic 
subfragments of the factor B molecule (14, 31), clone pFB2 could be a useful 
tool to generate definite truncated forms of factor B that express some of 
the important biological activities of this complement regulatory compo-
nent. 
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